KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Assets (2016 - 2025)

Historic Assets for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to $1.4 billion.

  • Neogenomics' Assets fell 1622.87% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year decrease of 1622.87%. This contributed to the annual value of $1.6 billion for FY2024, which is 256.9% down from last year.
  • Neogenomics' Assets amounted to $1.4 billion in Q3 2025, which was down 1622.87% from $1.4 billion recorded in Q2 2025.
  • In the past 5 years, Neogenomics' Assets registered a high of $1.9 billion during Q3 2021, and its lowest value of $1.4 billion during Q3 2025.
  • Its 5-year average for Assets is $1.7 billion, with a median of $1.7 billion in 2023.
  • In the last 5 years, Neogenomics' Assets surged by 621681.76% in 2021 and then crashed by 1622.87% in 2025.
  • Neogenomics' Assets (Quarter) stood at $1.9 billion in 2021, then decreased by 6.94% to $1.7 billion in 2022, then dropped by 3.38% to $1.7 billion in 2023, then dropped by 2.57% to $1.6 billion in 2024, then decreased by 16.07% to $1.4 billion in 2025.
  • Its Assets stands at $1.4 billion for Q3 2025, versus $1.4 billion for Q2 2025 and $1.6 billion for Q1 2025.